223 related articles for article (PubMed ID: 30630452)
1. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO).
Mikhail AI; Schön S; Simon S; Brown C; Hegbrant JBA; Jensen G; Moore J; Lundberg LDI
BMC Nephrol; 2019 Jan; 20(1):13. PubMed ID: 30630452
[TBL] [Abstract][Full Text] [Related]
2. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
5. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
[TBL] [Abstract][Full Text] [Related]
6. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
Jensen G; Gøransson LG; Fernström A; Furuland H; Christensen JH
Clin Nephrol; 2019 Apr; 91(4):246-253. PubMed ID: 30614439
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
Biggar P; Leistikow F; Walper A
Clin Nephrol; 2016 Dec; 86 (2016)(12):310-318. PubMed ID: 27737531
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
11. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
12. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
13. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
[TBL] [Abstract][Full Text] [Related]
15. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
Covic A; Mircescu G
Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
[TBL] [Abstract][Full Text] [Related]
17. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis.
Goh HJ; Lee KS; Kim TH; Kim KN; Lim HJ; Kim KS; Yang WJ; Jo JK
Drug Des Devel Ther; 2020; 14():5679-5687. PubMed ID: 33380788
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
